IN VITRO FERTILIZATION MARKET SIZE & SHARE ANALYSIS - GROWTH TRENDS & FORECASTS (2023 - 2028)
In most assisted reproductive technologies (ART), such as in vitro fertilization (IVF) and artificial insemination, sperm separation systems are used. These systems are critical for assisted reproductive technologies (ARTs) because they provide purified samples that can be used in subsequent procedures. These systems are crucial for ARTs as they provide purified samples for further procedures. Furthermore, the rising focus of companies on developing novel devices for use in assisted reproductive technology (ART) procedures conducted by fertility clinics and obstetrician-gynecologist (OB/GYN) practices is driving the market growth.
Sperm selection is crucial to assisted reproduction, influencing the success rate of the treatment cycle and offspring health. Although, in the current clinical sperm selection practices, bypassing almost all the natural selection barriers is a major concern. Additionally, the increasing focus of market players on developing novel devices for use in assisted reproductive technology (ART) procedures performed by fertility clinics and obstetrician-gynecologist (OB/GYN) practices is one of the major driving forces. For instance, in October 2020, Trivector Biomed LLP introduced the ZyMōt sperm separation device, a new-age ‘Lab-On-Chip’ IVF solution in India. These separation devices are cutting-edge lab-on-a-chip technologies that use microfluidics and micro-filtration technology to efficiently isolate the healthiest, fastest-progressing sperm for the best possible results. Thus, as the male factor accounts for nearly half of all infertility cases, the development of a novel method that eliminates many potentially harmful phases of sperm handling in the lab is a much-needed medical intervention in the IVF field, and thus it is expected to drive the growth of the market.
Technological advancements in the sperm separation segment is another reason for driving the market segment. For instance, in March 2022, Malta, in an international collaboration with Pera Labs’s commercialization advisors at the University City Science Center, started the research and development of an AI-powered sperm and egg selection technology for fertility treatments. Pera Labs’s Malta operations have been accelerated by the EUR 800,000 of financial support from Malta Enterprise, coupled with Pera Labs’s financing.
Comments
Post a Comment